Raleukin
| Code | Size | Price |
|---|
| TAR-T10317-50mg | 50mg | £1,163.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Anakinra (Raleukin) is an antagonist of recombinant, nonglycosylated human IL-1R. It is the first biological agent to block the pro-inflammatory effects.
CAS:
143090-92-0
Formula:
C759H1186N208O232S10
Molecular Weight:
17257.6
Pathway:
Immunology/Inflammation
Purity:
0.98
SMILES:
0
Target:
IL Receptor
References
1. Cvetkovic RS, et al. Anakinra. BioDrugs. 2002;16(4):303-11; discussion 313-4.
2. McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant. 2012 Feb;12(2):322-9.
3. Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. Anticancer Res. 2010 Oct;30(10):3959-65.